125 related articles for article (PubMed ID: 1634140)
1. ras oncogene product p21 expression and prognosis of human ovarian tumors.
Yaginuma Y; Yamashita K; Kuzumaki N; Fujita M; Shimizu T
Gynecol Oncol; 1992 Jul; 46(1):45-50. PubMed ID: 1634140
[TBL] [Abstract][Full Text] [Related]
2. [Immunohistochemical studies of ras oncogene product p21 in human ovarian tumors].
Yaginuma Y; Yamashita K
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1409-16. PubMed ID: 2685141
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometric analysis of DNA content and RAS P21 oncoprotein expression in ovarian neoplasms.
Kotylo PK; Michael H; Fineberg N; Sutton G; Roth LM
Int J Gynecol Pathol; 1992; 11(1):30-7. PubMed ID: 1563907
[TBL] [Abstract][Full Text] [Related]
4. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types.
Kabawat SE; Bast RC; Welch WR; Knapp RC; Colvin RB
Am J Clin Pathol; 1983 Jan; 79(1):98-104. PubMed ID: 6336888
[TBL] [Abstract][Full Text] [Related]
5. On the histogenesis and morphology of ovarian carcinomas.
Dallenbach-Hellweg G
J Cancer Res Clin Oncol; 1984; 107(2):71-80. PubMed ID: 6715398
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical detection of the ras oncogene product p21 in advanced ovarian cancer. Lack of correlation with clinical outcome.
Rodenburg CJ; Koelma IA; Nap M; Fleuren GJ
Arch Pathol Lab Med; 1988 Feb; 112(2):151-4. PubMed ID: 3276289
[TBL] [Abstract][Full Text] [Related]
7. K-ras gene point mutations and p21ras immunostaining in human ovarian tumors.
Semczuk A; Postawski K; Przadka D; Rozynska K; Wrobel A; Korobowicz E
Eur J Gynaecol Oncol; 2004; 25(4):484-8. PubMed ID: 15285310
[TBL] [Abstract][Full Text] [Related]
8. Periodic acid-Schiff stain as a prognostic indicator in serous and mucinous ovarian tumors.
Aalto ML; Collan Y
Int J Gynaecol Obstet; 1986 Feb; 24(1):27-34. PubMed ID: 2874066
[TBL] [Abstract][Full Text] [Related]
9. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas.
Zheng J; Benedict WF; Xu HJ; Hu SX; Kim TM; Velicescu M; Wan M; Cofer KF; Dubeau L
J Natl Cancer Inst; 1995 Aug; 87(15):1146-53. PubMed ID: 7674319
[TBL] [Abstract][Full Text] [Related]
10. Expression of ras oncogene p21 protein in normal and neoplastic ovarian tissues: correlation with histopathologic features and receptors for estrogen, progesterone, and epidermal growth factor.
Scambia G; Catozzi L; Panici PB; Ferrandina G; Coronetta F; Barozzi R; Baiocchi G; Uccelli L; Piffanelli A; Mancuso S
Am J Obstet Gynecol; 1993 Jan; 168(1 Pt 1):71-8. PubMed ID: 8420353
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of ras p21 oncoprotein in undifferentiated and well-differentiated epithelial carcinomas of the human ovary.
Kuwashima Y; Shisa H; Uehara T; Kurosumi M; Kobayashi Y; Tanuma J; Shiromizu K; Matsuzawa M; Kishi K
Anticancer Res; 1995; 15(6B):2847-50. PubMed ID: 8669877
[TBL] [Abstract][Full Text] [Related]
12. Hepatobiliary cystadenoma and cystadenocarcinoma. A light microscopic and immunohistochemical study of 70 patients.
Devaney K; Goodman ZD; Ishak KG
Am J Surg Pathol; 1994 Nov; 18(11):1078-91. PubMed ID: 7943529
[TBL] [Abstract][Full Text] [Related]
13. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
14. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology.
Mandai M; Konishi I; Kuroda H; Komatsu T; Yamamoto S; Nanbu K; Matsushita K; Fukumoto M; Yamabe H; Mori T
Hum Pathol; 1998 Jan; 29(1):34-40. PubMed ID: 9445131
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer.
Harada M; Dosaka-Akita H; Miyamoto H; Kuzumaki N; Kawakami Y
Cancer; 1992 Jan; 69(1):72-7. PubMed ID: 1309311
[TBL] [Abstract][Full Text] [Related]
17. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
[TBL] [Abstract][Full Text] [Related]
18. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.
Mok SC; Bell DA; Knapp RC; Fishbaugh PM; Welch WR; Muto MG; Berkowitz RS; Tsao SW
Cancer Res; 1993 Apr; 53(7):1489-92. PubMed ID: 8384077
[TBL] [Abstract][Full Text] [Related]
19. Expression of c-myc and mutation of the KRAS gene in patients with ovarian mucinous tumors.
Li XS; Sun J; He XL
Genet Mol Res; 2015 Sep; 14(3):10752-9. PubMed ID: 26400304
[TBL] [Abstract][Full Text] [Related]
20. p63 expression in epithelial ovarian tumors.
Poli Neto OB; Candido Dos Reis FJ; Zambelli Ramalho LN; Nogueira AA; de Andrade JM
Int J Gynecol Cancer; 2006; 16(1):152-5. PubMed ID: 16445626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
